Rhumbline Advisers Increases Stake in Hologic, Inc. (NASDAQ:HOLX)

Rhumbline Advisers increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 5.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 535,348 shares of the medical equipment provider’s stock after buying an additional 25,822 shares during the period. Rhumbline Advisers owned about 0.24% of Hologic worth $33,068,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its position in shares of Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after buying an additional 1,606 shares during the last quarter. Groupama Asset Managment lifted its stake in shares of Hologic by 63.4% in the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider’s stock worth $3,918,000 after acquiring an additional 21,037 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of Hologic in the 4th quarter worth $4,215,000. Signaturefd LLC lifted its stake in shares of Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider’s stock valued at $212,000 after purchasing an additional 754 shares during the period. Finally, Brevan Howard Capital Management LP lifted its stake in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider’s stock valued at $1,401,000 after purchasing an additional 8,960 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on HOLX shares. Evercore ISI reduced their price objective on shares of Hologic from $65.00 to $62.00 and set an “in-line” rating for the company in a research note on Friday, May 2nd. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Raymond James restated an “outperform” rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus target price of $77.42.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $62.57 on Thursday. The company has a market cap of $13.94 billion, a PE ratio of 19.74, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a 50-day simple moving average of $58.19 and a 200-day simple moving average of $65.65.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the firm earned $1.03 earnings per share. Hologic’s revenue was down 1.2% compared to the same quarter last year. On average, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.88% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.